As you know the result of the CheckMate 648 was already published in the New England Journal of Medicine. This shows superiority of the nivo-chemo and the nivo-ipi over chemotherapy alone in patients with esophageal squamous cell carcinoma.
After the follow-up of the 29 months, the consistent superiority of the nivo-chemo and the nivo-ipi was observed over chemotherapy alone. The difference is the long-term follow-up result does slightly improved the hazard ratio of the OS was seen in the nivo-ipi arm compared to the primary result...
As you know the result of the CheckMate 648 was already published in the New England Journal of Medicine. This shows superiority of the nivo-chemo and the nivo-ipi over chemotherapy alone in patients with esophageal squamous cell carcinoma.
After the follow-up of the 29 months, the consistent superiority of the nivo-chemo and the nivo-ipi was observed over chemotherapy alone. The difference is the long-term follow-up result does slightly improved the hazard ratio of the OS was seen in the nivo-ipi arm compared to the primary result.
So that mean that duration of the response was more seen in the ipi-nivo arm. And indeed no safety profile was changing and no new signal of the immune-related toxicity was seen even after the longer follow-up time.